According to the Shanghai Pharmaceutical announcement, Shangyao Dongying Pharmaceutical Co., Ltd., a subsidiary of the company, has received the “Drug Registration Certificate” for injectable isaconazole sulfate issued by the State Drug Administration, and the drug has been approved for production. This drug is a class 4 chemical, with a specification of 0.2 g. It is suitable for treating aggressive aspergillosis and invasive furuncles in adults and children aged 1 year and above. As of the announcement date, the company had invested about 16.813,300 yuan in R&D expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 315 million yuan. The approval of the drug is conducive to expanding market share and enhancing competitiveness, but there is uncertainty about the sales situation.

According to the Shanghai Pharmaceutical announcement, Shangyao Dongying Pharmaceutical Co., Ltd., a subsidiary of the company, has received the “Drug Registration Certificate” for injectable isaconazole sulfate issued by the State Drug Administration, and the drug has been approved for production. This drug is a class 4 chemical, with a specification of 0.2 g. It is suitable for treating aggressive aspergillosis and invasive furuncles in adults and children aged 1 year and above. As of the announcement date, the company had invested about 16.813,300 yuan in R&D expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 315 million yuan. The approval of the drug is conducive to expanding market share and enhancing competitiveness, but there is uncertainty about the sales situation.